Objective: To describe the prepubertal growth pattern in boys with delayed puberty. Methods: Growth curves for height and height velocity covering the age range 4–14 years were constructed on the basis of retrospectively obtained data in 85 boys with delayed puberty, who attained a normal final height. Results: Between the age of 4 and 14 years the height in this cohort progressively deviated from the normal reference. At the age of 4 years, the height SDS was already significantly lower (median –0.8; p < 0.001) and progressively diminished during childhood, resulting in a median height SDS of –1.1 at the age of 12 years (p < 0.001). The median final height of this cohort (–0.4) was not different from their target height (–0.2). The degree of deceleration in growth during childhood was not determined by birth weight or birth height and did not influence final height. The decline of the height velocity with age in this group of boys with delayed puberty was significantly smaller (p < 0.001) than predicted by the model of Rikken and Wit. Conclusion: Late-maturing boys often show a prepubertal deceleration in growth that starts at an early age but that does not affect final height.

Keywords:
Height, Height velocity, Growth retardation, Constitutional delay in growth and puberty
1.
Tanner JM, Davies PSW: Clinical longitudinal standards for height and height velocity for North American Children. J Pediatr 1985;107:317–329.
2.
Rikken B, Wit JM: Prepubertal height velocity references over a wide age range. Arch Dis Child 1992;67:1277–1280.
3.
Karlberg J: A biologically-oriented mathematical model (ICP) for human growth. Acta Paediatr Suppl 1989;350:70–94.
4.
Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA: Cross-sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17–24.
5.
Tanner JM, Goldstein H, Whitehouse RH: Standards for children’s height at ages 2–9 years allowing for height of parents. Arch Dis Child 1970;45:755.
6.
Ranke MB: Towards a consensus on the definition of idiopathic short stature. Horm Res 1996;45(suppl 2): 64–66.
7.
Niklasson A, Karlberg P: Weight-for-length model in newborn Swedish infants. Acta Paediatr 1993;82:333–339.
8.
Greulich WN, Pyle S: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1983.
9.
Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity and weight velocity: British children, 1965. Arch Dis Child 1966;41:613–635.
10.
Albanese A, Stanhope R: Predictive factors in the determination of final height in boys with constitutional delay of growth and puberty. J Pediatr 1995;126:545–550.
11.
Crowne EC, Shalet SM, Wallace WHB, Eminson DM, Price DA: Final height in boys with untreated constitutional delay in growth and puberty. Arch Dis Child 1990;65:1109–1112.
12.
Sperlich M, Butenandt O, Schwarz HP: Final height and predicted height in boys with untreated constitutional growth delay. Eur J Pediatr 1995;154:627–632.
13.
LaFranchi S, Hanna CE, Mandel SH: Constitutional delay of growth: Expected versus final adult height. Pediatrics 1991;87:82–87.
14.
Rochiccioli P, Tock Mine YY, Enjaume C, Dutau G, Sablayrolles B: Le retard de maturation osseuse est un élément favorable du pronostic de la taille définitive. Arch Fr Pédiatr 1985;42:273–276.
15.
Rensonnet C, Kanen F, Coremans C, Ernould C, Adelin A, Bourguignon J-P: Pubertal growth as a determinant of adult height in boys with constitutional delay of growth and puberty. Horm Res 1999;51:223–229.
16.
Gourmelen M, Pham-Huu-Trung MT, Girard F: Transient partial GH deficiency in prepubertal children with delay of growth. Pediatr Res 1979;13:221–224.
17.
Bierich JR: Serum growth hormone levels in provocation tests and during nocturnal spontaneous secretion: A comparative study. Acta Paed Scand 1987;337(suppl):48–59.
18.
Adan L, Souberbielle JC, Brauner R: Management of the short stature due to pubertal delay in boys. J Clin Endocrinol Metab 1994;78:478–482.
19.
Saggese G, Cesaretti G, Giannessi N, Bracaloni C, Cinquanta L, Cioni C: Stimulated growth hormone (GH) secretion in children with delay in pubertal development before and after the onset of puberty: Relationship with peripheral plasma GH-releasing hormone and somatostatin levels. J Clin Endocrinol Metab 1992;74:272–278.
20.
Wu FCW, Brown DC, Butler GE, Stirling HF, Kelnar CJH: Early morning plasma testosterone is an accurate predictor of imminent pubertal development in prepubertal boys. J Clin Endocrinol Metab 1993;76:26–31.
21.
Mitamura R, Yano K, Suzuki N, Ito Y, Makita Y, Okuno A: Diurnal rhythms of luteinizing hormone, follicle-stimulating hormone, and testosterone secretion before the onset of male puberty. J Clin Endocrinol Metab 1999;84:29–37.
22.
Zachmann M, Studer S, Prader A: Short-term testosterone treatment at bone age of 12 to 13 years does not reduce adult height in boys with constitutional delay of growth and adolescence. Helv Paediatr Acta 1987;42:21–28.
23.
Schroor EJ, Van Weissenbruch MM, Knibbe P, Delemarre-van de Waal HA: The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty. Eur J Pediatr 1995;154:953–957.
24.
Wilson DM, McCauley E, Brown DR, Dudley R: Oxandrolone therapy in constitutionally delayed growth and puberty. Pediatr 1995;96:1095–1100.
25.
Arrigo T, Cisternino M, De Luca F, Saggese G, Messina MF, Pasquino AM, De Sanctis V: Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty. J Pediatr Endocrinol Metab 1996;9:511–517.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.